NetScientific said portfolio company Vortex BioSciences has achieved its first direct commercial sale of an automated system that collects intact circulating tumor cells.
Vortex's VTX-1 Liquid Biopsy System automates the capture and collection of viable CTCs directly from whole blood for analysis.
"We are delighted to announce the first sale of Vortex's VTX-1, which represents an important step in the company's commercialisation journey," NetScientific chief executive Francois Martelet said.
"The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer."
At 8:21am: (LON:NSCI) Netscientific Plc share price was +3.75p at 63.5p